Cambridge Innovation Capital Becomes Latest Partner of One Nucleus

Cambridge, UK: 31 March 2021 - One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes facilitating connections between companies and with investors. Cambridge Innovation Capital (CIC), the renowned investor backing and building world-leading deeptech and life sciences companies in the Cambridge ecosystem, has become the latest company to join the One Nucleus Partner Programme. The programme is tailor-made to meet the needs of the Partner and One Nucleus members.

Michael Anstey, Partner at CIC commented, “CIC is committed to investing in excellent, early-stage companies that build into highly successful, global businesses. We have a collaborative approach and are a preferred investor for the University of Cambridge. Joining the One Nucleus Partner Programme brings further opportunities for CIC to contribute to the ecosystem and support our portfolio companies”.

Tony Jones, CEO of One Nucleus expands further ‘We are delighted to welcome CIC to the One Nucleus Partner Programme given their pivotal role in the region’s ecosystem. Their track record of founding and accelerating the growth of innovative companies speaks for itself. I feel engaging in this strategic manner will bring value to them, their portfolio companies and One Nucleus members. One Nucleus is entirely focussed on bringing great innovation, leadership and investment together to enable translation of world class science to patient benefit and strong returns for all stakeholders. CIC brings immense expertise, connectivity and capacity to help us in that endeavour.’

Media Contact Information: 

Tony Jones, CEO

Tel: +44 (0)1223 896463